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Abstract 
Vascular endothelial growth factor (VEGF) is generated as two contrasting isoform 
families in terms of their actions on vascular permeability, angiogenesis and 
vasodilatation, but both families are cytoprotective for epithelial and endothelial cells. 
The pro-angiogenic VEGF165a isoform has been shown also to be neuroprotective in 
hippocampal, dorsal root ganglia and retinal neurones, but the effect of the 
contrasting VEGF165b isoform is unknown. We therefore tested the hypothesis that 
the VEGF165b isoform may be an endogenous neuroprotective agent for 
hippocampal, retinal and DRG neurons.  
RESULTS. Endogenous expression of human and rat VEGF165b was detected in 
hippocampal and cortical neurons and formed a significant proportion of total VEGF 
in rat brain. Recombinant human (rh)VEGF165b exerted neuroprotective effects on 
several different neuronal types exposed to different insults, including glutamatergic 
excitotoxicity in hippocampal neurons, chemotherapy induced cytotoxicity of dorsal 
root ganglion cells and retinal ganglion cells in rat retinal ischemia-reperfusion injury 
in vivo. Protection against excitotoxic damage was dependent on VEGFR2 
activation, and p42/p44MAPK.   
CONCLUSIONS. rhVEGF165b is a neuroprotective agent that effectively protects 
both peripheral and central neurons in vivo and in vitro, through VEGFR2, MEK1/2 
and inhibition of caspase-3 induction, with no requirement for neuropilin binding. 
VEGF165b may be therapeutically useful for pathologies involving neuronal damage, 
including hippocampal neurodegeneration, glaucoma diabetic retinopathy and 
peripheral neuropathy, whilst non-isoform specific inhibition of VEGF (for anti-
angiogenic reasons) may be damaging to retinal and sensory neurons.
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Introduction. 
VEGF-A, originally described as a potent vascular permeability and growth 
factor for endothelial cells is upregulated in the brain during stroke and ischaemic 
episodes (Z. Kovacs et al., 1996) and has been linked with many neuronal diseases. 
The most widely studied isoform of VEGF, VEGF165a, is upregulated in hypoxia, 
induces increased vascular permeability in neuronal vasculature, and can stimulate 
angiogenesis after ischemic episodes. The resulting oedema and hyperaemia can be 
damaging, but VEGF165a has also been shown to have direct anti-cytotoxicity effects 
on neurons, raising the possibility that it may act as an endogenous neuroprotective 
agent. VEGF also exerts neurotrophic (survival), and neurotropic (neurogenesis, 
axon outgrowth) actions, which, although initially thought to be a function of 
increased angiogenesis and perfusion after neuronal injury (M. I. Hobson et al., 
2000), are now appreciated as direct effects of VEGF on neurones.  
The vegf-a gene encodes numerous products by differential splicing, but not 
all isoforms exert the same effects (S. J. Harper and D. O. Bates, 2008). Alternative 
splicing of exon 8 leads to two functionally distinct families - the pro-angiogenic 
VEGFxxxa family and the counteracting VEGFxxxb family (D. O. Bates et al., 2002; J. 
Woolard et al., 2004). VEGF165b prevents the VEGF165a effects on increased 
vascular permeability, blood vessel growth and vasodilatation. However, VEGF165b 
acts in the same way as VEGF165a on epithelial and endothelial survival, being 
cytoprotective for retinal-pigmented epithelial cells, visceral glomerular epithelial cells 
(podocytes), and umbilical vein endothelial cells (H. S. Bevan et al., 2008; A. L. 
Magnussen et al., 2010). 
The therapeutic potential of VEGF and anti-VEGF treatments are now widely 
recognized and anti-VEGF treatments are available in ophthalmology and oncology. 
The findings that VEGF is implicated in neuronal disorders e.g. Alzheimer’s disease, 
Parkinson’s disease, Huntington’s disease, diabetic neuropathy, and ALS (see 
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review (E. Storkebaum et al., 2004)), provide a rationale for the use of VEGF as a 
therapeutic in neurodegenerative conditions. Although this is supported by preclinical 
evidence (M. Sondell et al., 1999) the identification of the VEGFxxxb family requires 
re-examination of VEGF isoforms in these contexts, to allow for the clear evidence 
that VEGF splicing variants are not functionally equivalent (S. J. Harper and D. O. 
Bates, 2008), and to determine whether augmentation of the pro-angiogenic isoform 
family (VEGFxxxa) alone may have deleterious effects (eg in occult malignancy, 
carcinoma in situ etc). 
The neuroprotective profile of the exon 8 alternatively spliced isoforms VEGFxxxb 
remains unexplored. Interestingly, VEGFxxxb isoforms do not exhibit the vascular 
effects seen with VEGFxxxa isoforms, such as a sustained increase in capillary 
permeability or hypotension(J. Woolard et al., 2004; C. A. Glass et al., 2006) The 
lack of these potential adverse effects may make VEGFxxxb isoforms more amenable 
as therapeutic agents in neurodegenerative diseases. 
We therefore tested the hypothesis that VEGF165b is neuroprotective for central 
and peripheral neurones. We show that VEGF165b is expressed in central neurones, 
and is neuroprotective in vitro, and in vivo. This indicates that VEGF165b may prove to 
be a suitable therapeutic agent in neurodegenerative disorders, exhibiting fewer 
adverse effects than VEGF165a.
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Materials and Methods 
All reagents were sourced from Sigma-Aldrich (Dorset, UK) unless otherwise 
stated. Antibodies were sourced from R&D systems (Carlsbad, CA): αVEGF165b, 
(MAB 3045); α−caspase-3; αTrkA and αNF-200. Recombinant human (rh)VEGF165b 
was provided by Philogene, New York or from R&D Systems (Carlsbad). Computer-
aided analysis of immunohistochemistry, retinal Fluorogold staining, and cytotoxicity 
was performed using Macintosh computers running public domain Image J plus Cell 
Counter Plugin (developed at the U.S. National Institutes of Health and available on 
the Internet at http://rsb.info.nih.gov/nih-image/). 
 
VEGF protein was localized in fixed or frozen tissue sections using standard 
immunohistochemical/immunofluorescent techniques (H. S. Bevan et al., 2008) or 
was measured in tissue extracts by commercially available ELISA, or Western 
blotting as previously described (J. Woolard et al., 2004). Total VEGF and VEGF165b 
were detected using validated, commercially available antibodies. The VEGF165b 
antibody detects the unique C-terminal of the alternatively spliced VEGFxxxb family (J. 
Woolard et al., 2004; A. H. Varey et al., 2008).  
 
Human embryonic and adult tissues were obtained under ethical approval by 
North Bristol NHS Trust or University of Leiden. All procedures using animals were 
performed in accordance with the United Kingdom Animals (Scientific Procedures) 
Act 1986 and with University of Bristol Ethical Review Panel approval. 
 
Glutamate-induced hippocampal neuronal excitotoxicity was assessed in cultures 
of neonatal hippocampal neurons from twelve 2-day old CD1 mouse pups as 
previously described (C. R. Elliott-Hunt et al., 2004). Neurons were cultured on poly-
lysine coated glass cover slips in 6 well plates (37°C, ambient oxygen and 5% CO2, 
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400,000 cells/ plate) in neuronal growth media plus B-27 supplement, (GIBCO-
Invitrogen, Paisley, UK) with penicillin and streptomycin and 1% BSA. After 24 hours 
cultures were supplemented with 10µg/ml 5-fluoro-2’-deoxyuridine to inhibit growth of 
non-post-mitotic cells. Excitotoxicity assays started on day 10 of culture. Cultures 
were exposed to 3mM L-glutamic acid for 24 hours in the presence of VEGF165b 
(0.01, 0.1, 1 and 10nM) or 50nM galanin (Bachem). To determine the mechanism of 
VEGF165b-mediated effects, additional cultures were incubated with VEGF165b in the 
presence of VEGF receptor, and downstream signalling molecule inhibitors PTK787 
(Novartis), SU5416 (Sugen), ZM323881 (Astra Zeneca) and PD98059 (Calbiochem). 
Cytotoxicity was assessed by a trained observer blinded to treatment using a 
Live/Dead® Viability/Cytotoxicity Kit (Molecular Probes-Invitrogen, Paisley, UK). The 
cells were fixed and nuclei stained (Hoechst 33258; 1:2300) and mounted to a glass 
slide. Ten random images of each cover slip were taken.  
 
Oxaliplatin-induced dorsal root ganglion (DRG) neuronal death was assessed in 
primary cultures of adult rat dorsal root ganglion neurons. DRG were dissected, 
enzymatically and mechanically dissociated, and cells plated onto poly-L-lysine- and 
laminin-coated coverslips at ~2,850 cells/cm2. 5-Fluoro-2’-deoxyuridine (30µg/mL) 
was added to prevent non-post-mitotic cells from proliferating. DRG neurons were 
cultured for 2 days before overnight pre-treatment with test compounds (2.5nM 
VEGF165b or vehicle). Neurons were then treated with oxaliplatin for 24 hours at 0, 5, 
10 or 20µg/mL with 2.5nM VEGF165b or vehicle. Following treatment, neurons were 
fixed in 4% PFA and subjected to immunofluorescence for the detection of activated 
caspase 3 (rab mAb, 200ng/mL, overnight, Cell Signaling). Neurons were identified 
by co-staining with markers NeuN, βIII-tubulin or neuron-specific enolase-1 (NSE-1). 
The percentage of caspase-3-positive neurons were analysed by a trained observer 
blinded to treatment. In separate experiments VEGFR2 expression was detected 
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using a rabbit VEGFR2 mAb (1:500, overnight, Cell Signaling, 50b11). The primary 
antibody was replaced by concentration- and species-matched IgG to control for 
each immunofluorescence experiment. 
 
The effect of VEGF165b on neurite outgrowth in cultured rat DRG neurones was 
assessed as previously described (F. E. Holmes et al., 2000). Adult DRG neurones 
were cultured with or without 2.5nM VEGF165b for 24 hours, and the length of neurite 
outgrowth assessed. 
 
A total of 27 male Wister rats (250-350g, Charles River, Germany) were used to 
assess the effect of VEGF165b on retinal ganglion cell (RGC) death following 
ischemia. One week before ischaemia/reperfusion injury, retinal ganglion cells were 
retrogradely labelled with fluorogold using a previously described method (I. Selles-
Navarro et al., 1996; T. Jehle et al., 2008). Briefly, Fluorogold (4% in PBS, 
Fluorochrome Inc., Denver, CO) was injected into bilateral superior colliculi (0.6µl at 
4.2mm and 0.7µl at 4.7mm depth) under isoflurane inhalation anaesthesia (one 
minute induction at 5% in O2, reduced to 3% for maintenance) and sterotaxic 
guidance. Fluorogold is retrogradely transported in RGCs and somatic labelling is 
maintained for at least three weeks (A. K. Ahmed et al., 1995). Animals were 
randomly assigned to one of three groups: 12 animals received an intravitreal 
injection of 10ng VEGF165b in 5µl HBSS, 7 received the same volume of HBSS and 8 
were untreated. 24 hours after intraocular injection animals were subject to retinal 
ischemia as previously described (I. Selles-Navarro et al., 1996; T. Jehle et al., 
2008). Under Isoflurane anaesthesia and stereotaxic guidance, the pupil was dilated 
(1% tropicamide and 2.5% phenylepherine eye drops), and anterior chamber 
pressure was maintained for 60 minutes with 0.9% NaCl infusion that elevated the 
intraocular pressure to 120 mm Hg. The cessation of the retinal blood flow was 
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observed using direct fundoscopy during the procedure. Reperfusion of retinal 
vessels was observed as intraocular pressure reduced after cessation of perfusion. 
Twenty-four hours after ischemia, retinas from three animals from each group were 
stained for activated caspase-3 immunofluorescence to assess the extent of 
ischemic damage (T. T. Lam et al., 1999). Caspase-3 positive cells were counted 
independently in the retinal ganglion and inner nuclear layers. The remaining animals 
were killed with isoflurane overdose ten days after ischemia and the numbers of 
surviving Fluorogold labelled neurones counted. Cell counts were performed by an 
operator blinded to treatment.  
Partial saphenous nerve injury (PSNI) on C57/Bl6 mice was carried out as 
previously described(J. S. Walczak et al., 2005) under isofluorane anesthesia (2-3% 
in O2). A ~5mm incision was made in the inguinal fossa region of the right hind leg. 
50% of the saphenous nerve was tightly ligated using a size 6.0 sterile silk suture 
and the wound was closed with size 4.0 sterile silk suture. Sham-operated animals 
(n=5) underwent anesthesia and surgery involving solely an incision in the inguinal 
fossa region of the right hind limb. Each PSNI experimental group received biweekly 
VEGF165b (n=6, 20ng/g) or PBS vehicle (n=16, 200µl). Sham surgery involved the 
exact same procedure, except without the tight ligation of the saphenous nerve. 
Sham operated controls (n=5) received i.p. PBS at the same times. Injections were 
given immediately after surgery, and animals were killed after 10 days by overdose 
of anaesthetic and perfuse fixation with 4% paraformaldehyde. DRG were dissected 
out, frozen, sectioned at 10µm thickness and stained for ATF3 (cat no sc188, Santa 
Cruz).  
 
Statistical analysis 
Numbers of repetitions/animals are given in the text and/or Figure legends. All 
data were analysed using or t-tests (2 groups), 1 way ANOVA and appropriate post-
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hoc tests (3 or more groups), unless data were ordinal or obviously non-Gaussian, in 
which case non-parametric equivalents were used.  
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Results 
VEGFxxxb: Endogenous neuronal expression.  
Immunohistochemistry of human brain samples demonstrated that VEGF165b was 
strongly expressed in the human hippocampal region, throughout all three pyramidal 
regions (CA1, CA2 and CA3), and the dentate gyrus, in neurons as well as being 
expressed in occasional neurons scattered through the cortex (Figure 1A). To 
quantify expression, protein was extracted from rat brains, and VEGF165b and total 
VEGF levels measured by ELISA. VEGF165b levels averaged 45% and 41% of total 
VEGF in the cortex and hippocampus respectively (Figure 1Bi-ii).  
As VEGFxxxa splice variants are known to be neuroprotective, we assessed the 
effectiveness of VEGFxxxb splice variants as neuroprotective agents in hippocampal 
neurons, CNS neurons that are particularly vulnerable to damage.  
Recombinant human VEGF165b reversed glutamate-induced hippocampal 
neuronal death in a concentration-dependent manner (Figure 2A, B), and was more 
potent than galanin, which has previously been described as a potent hippocampal 
neuroprotective agent (C. R. Elliott-Hunt et al., 2004) (Figure 2B). At 10nM, the 
maximum VEGF165b concentration used, cell death was the same as untreated cells, 
showing complete inhibition of excitotoxicity. VEGF165b is a weak partial agonist at 
VEGF receptor 2 (VEGFR2, a.k.a. Flk1) in vitro (H. Kawamura et al., 2008a). In 
hippocampal neurones, the neuroprotective action of VEGF165b was dependent on 
VEGFR2 activation (Figure 2C), as has been described for VEGF165a (H. Matsuzaki 
et al., 2001). The partial reversal of excitotoxic cell death seen in the presence of 
VEGF165b was blocked by the VEGFR blockers PTK787 (100nM, blocks both 
VEGFR1 and VEGFR2, (J. M. Wood et al., 2000)) and ZM323881 (10nM, blocks 
VEGFR2, (C. E. Whittles et al., 2002)) but was unaffected by SU5146 (at 100nM has 
specificity for VEGFR1, (C. A. Glass et al., 2006)). Hippocampal neurons in culture 
expressed VEGFR2 (Figure 2D). Hippocampal neuroprotection elicited by VEGF165b 
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was dependent on downstream signalling of the VEGFR through the p42/p44MAPK 
pathway (Figure 3A), as it was also blocked by the MEK2 inhibitor, PD98059 (10µM), 
as is also the case for VEGF165a. Neuroprotection was not affected by blockade of 
either p38 MAP kinase by SB203580, or PI3 kinase (PI3K) with LY294002 (Figure 
3A, B).  
VEGF165b also exerted a neuroprotective action on retinal neurones in vivo (Figure 
4). In retinal ischaemia a reduction in retrograde transport of fluorescent tracer was 
seen (Figure 4Aii). This ischaemic neuronal loss was reversed by prior intraocular 
VEGF165b treatment (Figure 4Aiii). To determine whether this was due to apoptosis, 
retinae were stained for active caspase-3 (Figure 4B). Un-injected and HBSS-
injected ischaemic eyes showed significant retinal neuronal loss through apoptosis, 
as assessed by fluorogold labelling of live neurones (Figure 4C-D), and caspase-3 
staining respectively (Figure 4E). The reduction in neuronal retrograde transport was 
significantly reversed by VEGF165b (Figure 4A,C-D), when compared to the un-
injected contralateral eye, and reduced apoptosis in both retinal ganglion cells and 
inner nuclear layer cells (Figure 4B, D).  
To determine whether neuroprotection was confined to central neurons or also 
affected peripheral neurons, cultured primary DRG neurones were investigated. The 
addition of 1nM VEGF165b significantly increased the length of neurite outgrowth over 
24 hours from 41.7±2.2µm to 73.8±20µm (p<0.05, Mann Whitney U test) but did not 
affect the number of DRG neurones in treated and control cultures. Staining of 
dispersed DRG neurons with VEGFR2 showed strong expression on the cell 
membrane (Figure 5A). VEGF165a has been shown to be cytoprotective against injury 
induced by a variety of cellular insults to neurones (D. Lambrechts et al., 2003). 
VEGF165b (2.5nM) significantly prevented an increase in activated caspase-3 in 
primary DRG neurons induced by 24 hours treatment with the chemotherapeutic 
oxaliplatin. Treatment with oxaliplatin alone (5, 10 or 20µg/mL) significantly increased 
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the percentage of caspase-3-positive DRG neurons compared to untreated neurons, 
and VEGF165b prevented this (Figure 5C).  
To investigate the receptor mediating the neuroprotective response to VEGF165b 
DRG cultures were treated with the specific VEGFR2 inhibitor ZM323881 (10nM) or 
vehicle during oxaliplatin treatment and stained for NeuN and activated caspase-3 
(Figure 5D). Treatment with 20µg/mL oxaliplatin, either alone or with ZM323881, 
induced a significant increase in the percentage of activated caspase-3-positive, 
NeuN-positive cells compared to media (51.4±3.0% and 55.7±1.9% vs. 37.8±1.3% 
and 42.5±2.6% respectively) (Figure 5D). Concurrent treatment with recombinant 
human VEGF165b (2.5nM) without ZM323881 significantly reduced the percentage of 
activated caspase-3-positive, NeuN-positive cells compared to vehicle (35.4±3.1%) 
(Figure 5D) and this effect was blocked by treatment with the VEGFR2 inhibitor 
ZM323881 (54.3±3.3%). 
To determine whether systemic administration of VEGF165b could be 
neuroprotective we used a mouse model of peripheral traumatic nerve injury that 
results in activation of injury-response genes in DRG neurons, such as galanin(R. 
Hulse et al., 2008), and ATF3 (Figure 6A). Treatment with rhVEGF165b biweekly 
reduced the intensity of ATF3 expression in L3/4 DRG compared to sham surgery 
controls after 10 days (Figure 6A & B).  
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Discussion 
We show here that, like VEGF165a, the splice isoform VEGF165b is 
neuroprotective in central and peripheral neurones, in vitro and in vivo, and mediates 
this neuroprotective effect through VEGFR2 and MEK1/2 activation. In addition to its 
neuroprotective effects, VEGF165b also has neurotropic actions on neurones.  
VEGF165a has been shown to play a key role in neuronal protection, in 
addition to its actions on the vasculature, directly protecting motoneurons under 
conditions of hypoxia, oxidative stress, and serum deprivation (B. Oosthuyse et al., 
2001). Disturbance of VEGF expression contributes to the development of 
amyotrophic lateral sclerosis in man (D. Lambrechts et al., 2003). VEGF and its 
receptors are also expressed in central and peripheral nervous system support cells 
such as astrocytes and Schwann cells, thereby also contributing to neuronal survival 
and growth (for reviews see (E. Storkebaum et al., 2004; I. Zachary, 2005)).  
In the CNS, VEGF165a protects hippocampal, cortical, and cerebellar granule 
neurones against numerous insults (K. L. Jin et al., 2000b, a; J. M. Rosenstein et al., 
2003; J. N. Nicoletti et al., 2008), through VEGFR2, signalling through activation of 
multiple intracellular pathways including PLC, PI3K and MEK1/2 (I. Zachary, 2005), 
whereas effects on supporting cells, such as Schwann cells, and astrocytes, are 
generally mediated through VEGFR1 (E. Storkebaum et al., 2004). In contrast, our 
data show that neuroprotection by VEGF165b in hippocampal neurons, although also 
mediated through VEGFR2, does not involve either PI3K or p38 MAPK. The 
VEGFxxxb isoforms compete for and inhibit VEGFxxx binding at VEGFR2 (J. Woolard 
et al., 2004; S. Cebe Suarez et al., 2006; H. Kawamura et al., 2008b), but the 
VEGFxxxb isoforms are not simply competitive inhibitors of the VEGFR2 as binding of 
VEGF165b results in differential tyrosine residue phosphorylation of VEGFR2 (H. 
Kawamura et al., 2008a). Neuroprotective and neurotrophic actions by VEGF165a 
may also involve the VEGF-co-receptor, neuropilin-1 (NP-1) (I. Zachary, 2005); 
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VEGF165b binds weakly to NP-1 , and does not require NP-1 binding to 
phosphorylate and activate VEGFR2 (H. Kawamura et al., 2008a). Our data support 
the conclusion that the differential VEGFR2 phosphorylation and MEK1/2 activation 
exerted by VEGF165b is sufficient to protect central and peripheral neurons, without 
NP-1 binding. Our data on both CNS and peripheral sensory neurons show that the 
neuroprotective mechanism of VEGF165b, is like VEGF165a, in that neuroprotection 
occurs through prevention of caspase-3 induction (I. Zachary, 2005).   
In the eye, endogenous VEGF is a survival factor for retinal ganglion cells, 
protecting against ischaemia-reperfusion injury (K. Nishijima et al., 2007), and 
preventing neuronal apoptosis without the necessity for NP-1 binding, as VEGF120 
(which lacks the NP-1 binding domain (H. Kawamura et al., 2008c)) also exerted 
neuroprotective effects. Our findings show that VEGF165b can reduce both retinal 
ganglion cell and inner nuclear cell loss, through VEGFR2 activation. The loss of 
neuronal retrograde transport is seen clinically in diabetic retinopathy as cotton wool 
spots under fundus examination, and the loss of ganglion cells contributes to vision 
loss in glaucoma(M. Almasieh et al.). We have previously shown that VEGF165b is 
cytoprotective for endothelial cells (A. L. Magnussen et al., 2010), while being anti-
angiogenic in the eye (J. Hua et al., 2010). Prevention of the ischemia-induced 
damage to neurones in the retina by VEGF165b would therefore also be a substantial 
advantage in therapeutic approaches for diabetic retinopathy, and glaucoma. 
In hippocampal and peripheral sensory cultured neurons, VEGF165b also 
enhances neurite outgrowth, demonstrating that VEGF165b exerts neurotrophic 
effects, also through VEGFR2. In CNS and PNS peripheral sensory and autonomic 
neurons, VEGF165a enhances neuronal neurite outgrowth in culture (M. Sondell et al., 
1999; I. Zachary, 2005; G. Lin et al., 2010). VEGFR2 is expressed in both the central 
and peripheral nervous systems, but often in different neuronal populations from 
VEGF-A proteins (M. Sondell and M. Kanje, 2001; T. Licht et al., 2011). These 
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different distributions suggest that VEGF isoforms exert paracrine actions on 
neurons, through which neuroprotective and neurotrophic effects may be mediated. 
We demonstrate that VEGF165b is a major VEGF-A splice variant commonly found in 
central and peripheral neurones, where it is well placed to exert such paracrine 
effects. VEGF165b is also expressed in human skin, prostate, and kidney, amongst 
other tissues (J. Woolard et al., 2004; R. O. Pritchard-Jones et al., 2007), where it 
could also exert paracrine effects on peripheral sensory neurons.  
VEGF165b has clear inhibitory effects on tumour growth (J. Woolard et al., 
2004; E. Rennel et al., 2008; A. H. Varey et al., 2008) but does not result in 
hypertension, angiogenesis and proteinuria (J. Woolard et al., 2004; E. S. Rennel et 
al., 2008; Y. Qiu et al., 2010). Our data show that VEGF165b has neuroprotective 
effects similar to those of VEGF165a, on central and peripheral neurones. VEGF-
dependent neovascularisation is key in the pathophysiology of many conditions, and 
anti-VEGF therapies have entered clinical practice in oncology (H. Hurwitz et al., 
2004), and ophthalmology (P. J. Rosenfeld et al., 2006). Following successful pre-
clinical studies of VEGF administration in neurodegenerative disease (M. Sondell et 
al., 1999; P. Schratzberger et al., 2000; P. Schratzberger et al., 2001; D. Lambrechts 
et al., 2003; T. Yasuhara et al., 2005), VEGF supplementation is now under trial for 
treatment of neuronal degenerative diseases, for instance in diabetic neuropathy (A. 
H. Ropper et al., 2009). Although effective in some patients, there has to be some 
concern about the safety profile of these strategies in relation to the potential 
compromise of non-endothelial tissue/cell function in which VEGF has been shown to 
have cytoprotective properties, particularly neurons (E. Storkebaum et al., 2004) and 
podocytes (R. R. Foster et al., 2003). We show that VEGFxxxb can exert similar 
neuroprotective and neurotropic effects with VEGFxxxa both centrally (e.g. 
hippocampal neurons in culture, and retinal neurons in vivo) and peripherally.  
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With the requirement that therapy for pathological conditions in which VEGF has 
been implicated should not adversely affect the function of the normal vasculature, or 
other cell types, we suggest that VEGF165b may be an alternative therapeutic agent 
in neurodegenerative conditions with fewer adverse vascular side effects.
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Figure legends 
Figure 1. VEGF165b is expressed in human and rat hippocampus.  
Human cortical sections from the Human Tissue Authority licensed South West 
Dementia Brain Bank were stained with an anti-VEGF165b antibody. A. Hippocampal 
staining in CA1, CA2, CA3 and dentate gyrus (DG). B. Protein was extracted from 
cortex and hippocampus dissected from rat brains (n=3) and subjected to ELISA for 
VEGF and VEGFxxxb . (i) VEGFxxx levels were estimated from the difference between 
total VEGF and VEGFxxxb. (ii) percent of total VEGF that is VEGFxxxb. 
 
Figure 2 VEGF165b is protective against glutamate-induced hippocampal neuronal 
excitotoxicity.  
A. i. Pseudocoloured image of cultured hippocampal neurons exposed to glutamic 
acid, with and without VEGF165b or galanin. Cells co-stained with Hoechst 33258 
nuclear stain (blue) and Dead stain (red) show as purple, and represent ~75% of 
glutamic acid treated neurones under control conditions. ii. Effect of treatment with 
10nM VEGF165b on excitotoxicity in neurons co-incubated with 3nM glutamate. B. 
VEGF165b has a concentration-dependent inhibitory effect on glutamatergic 
excitotoxicity in hippocampal neurons. VEGF165b was a more potent neuroprotective 
than galanin (p<0.0001, n=4, ANOVA + Newman-Keuls post-hoc test *p<0.01, 
**p<0.001 ns=non-significant). C. Effect of VEGF receptor inhibitors on the 
hippocampal neuroprotective effect of VEGF165b. (100nM PTK787 (nonspecific 
VEGFR2 antagonist), 10nM ZM323881 (VEGFR2 specific antagonist), 100nM 
SU5416 (VEGFR1 specific antagonist) **=p<0.01, *=p<0.05 compared with control, 
n=4/group). D. VEGFR2 (red) expression in β3 tubulin positive (green) neurons. 
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Nuclei are stained blue. Arrows show membrane staining shown in higher power in 
lower panel.  
 
Figure 3. The effect of intracellular kinase-pharmacological inhibition on VEGF165b 
hippocampal neuroprotection against L-glutamic acid-induced excitotoxicity. 
A. Panels display representative images of hippocampal neurons subjected to the 
Live/Dead cell viability stain after 24 hours treatment with 3mM L-glutamic acid in 
the presence of test compounds or respective vehicles. Neurons treated in culture 
media alone (neurobasal media) or L-glutamic acid + 2.5nM VEGF165b with or 
without 10µM SB203580 (p38 MAPK inhibitor) or 15µM LY294002 (PI3K inhibitor) 
maintained neurite projections (arrows). In the presence of L-glutamic acid + 
VEGF165b + 10µM PD098059 (MEK1/2 inhibitor) neurons retracted neurites 
(arrowheads). B. The percentage of red-stained (dead) nuclei per total nuclei 
stained was calculated. More neurons died when treated with the MEK1/2 inhibitor + 
VEGF165b (Figure 3B, PD), than when treated with VEGF165b and vehicle (Figure 3B, 
Control). Neither p38 MAPK (SB) nor PI3 kinase (LY) inhibition had any effect on the 
neuroprotection exerted by VEGF165b. (Data shown are mean±SEM, n=3/4 1-way 
ANOVA + Bonferroni post hoc comparison); glutamic acid + inhibitor/vehicle vs. 
media + inhibitor/vehicle, *p<0.05, **p<0.01, ***p<0.001; glutamic acid + VEGF165b + 
inhibitor/vehicle vs. glutamic acid + inhibitor/vehicle, #p<0.05, ##p<0.01, ###p<0.001; 
glutamic acid + VEGF165b + inhibitor vs. glutamic acid + VEGF165b + vehicle, +p0.05.) 
 
Figure 4. VEGF165b protects retinal neurons from ischemia induced cell death in 
vivo.  
A. Pseudo-coloured fluorescent images of retinal cells showing (i) the contralateral 
non-ischemic retina, (ii) ischaemic eye injected with HBSS, or (iii) ischaemic eye 
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injected with VEGF165b. B. Staining of retinae of HBSS or VEGF165b injected rats for 
activated caspase 3 (red) and nuclei (blue). C. Live retinal ganglion cell counts were 
significantly lower in ischemic eyes compared to non-ischemic eyes. VEGF165b 
treatment resulted in more viable retinal ganglion cells (n=8 HBSS, n=12 VEGF165b, 
p<0.001, ANOVA + Bonferroni post-hoc test). VEGF165b treatment increased the 
numbers of live fluorogold labelled retinal cells, compared to the HBSS and control 
untreated eyes, which can be clearly seen when D. the ratio of retinal ganglion cells 
per field in the ischemic/non-ischemic eyes were compared. E. Neuroprotection by 
VEGF165b was mediated through an inhibition of apoptosis, as indicated by a 
reduction in active caspase-3 staining, in both the retinal ganglion cells (RGC) and 
inner nuclear layer (INL). Data are means±SEM. *=p<0.05 **=p<0.01, ***=p<0.001 
compared with contralateral and ++=p<0.01 compared with HBSS. NS=not different 
from contralateral.  
 
 Figure 5. VEGF165b is cytoprotective for primary sensory neurons 
A. Primary cultured DRG were stained for βIII tubulin (green), VEGFR2 (red) and 
Hoechst (blue). βIII-tubulin-positive cells were also positive for VEGFR2, with the 
receptor detected in the soma (white arrow) and along cellular projections 
(arrowhead). Some VEGFR2 detection did not colocalize to βIII-tubulin (cyan arrow). 
The matched-species IgG negative control confirms the detection of VEGFR2 
expression. B. Effect of VEGF165b in a model of chemotherapeutic-induced 
neurotoxicity. Primary adult rat DRG cultures were treated with increasing 
concentrations (0, 5, 10, 20 µg/mL) of the chemotherapeutic oxaliplatin for 24 hours 
with or without 2.5nM VEGF165b (following 16h pre-treatment). The percentage of 
activated caspase-3-positive NeuN-positive cells was determined after 
immunofluorescence analysis. Panels display representative images of NeuN-
positive cells after treatment. NeuN negative cells (only blue or blue and red only) 
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were not counted. Arrows signify activated caspase-3 detected both around and in 
neuronal nuclei. C. The percentage of neurons positive for activated caspase-3 was 
determined after treatment with 20µg/mL oxaliplatin for 24 hours with or without 
2.5nM VEGF165b. VEGF165b treatment inhibited oxaliplatin-induced caspase-3 
expression. Data shown are mean±SEM, n=3. D. Treatment of DRG cultures with 
oxaliplatin + VEGF165b and the VEGFR2 inhibitor ZM323881 (10nM) blocked the 
neuroprotection exerted by VEGF165b alone, indicating this action is mediated 
through VEGFR2. ZM323881 did not affect the oxaliplatin-induced caspase-3 
induction. Data shown are mean±SEM, n=3, 1-way ANOVA + Bonferroni post hoc 
comparison; * = compared with no oxaliplatin; *=p<0.05, **=p<0.01., ***=p<0.001.. † 
= compared with concentration matched vehicle.,  +=p<0.05. Scale bars = 50µm for 
B 
Figure 6. VEGF165b is neuroprotective for DRG neurons in vivo. 
Partial saphenous nerve injury (PSNI), was performed on lightly anaesthetized 
C57BL/6 mice. Test compounds were administered biweekly by i.p. injection 
following surgery (20ng rhVEGF165b per g body weight or a matched volume of PBS) 
and L4 DRG were harvested 14 days later. DRG were cut into 10µm sections and 
for each DRG a complete cross-section profile was analyzed for ATF3 
immunofluorescence intensity. A. Panels display representative images of ATF3 
immunofluorescence intensities from ipsilateral L4 DRG and a species- and 
concentration- matched IgG negative control. B. Using Image J software the 
average pixel intensity was calculated for each DRG profile and expressed relative 
to the mean pixel intensity for sham operated L4 DRG. Results are mean±SEM, n=3 
per group, statistical analysis: Kruskal-Wallis + Dunn’s multiple comparison test: test 
group ipsilateral DRG intensity vs. sham-operated ipsilateral DRG, *p<0.05. Scale 
bar=500µm. 
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